Nordisk

Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions

Retrieved on: 
Tuesday, November 7, 2023
Science, Heart failure, Quality of life, Treatment, Comorbidity, Novo Nordisk, Diabetes, American Heart Association, Doctor of Philosophy, Research, Drug development, Risk, Partnership, Abstract, STEP, AWARE, Phenotype, SELECT, AHA, Nordisk, Pharmaceutical industry, Obesity

Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.

Key Points: 
  • Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.
  • Late-breaking scientific abstracts will be posted online at the exact date and time the embargo lifts.
  • Data from the SELECT trial will be presented live during a late-breaking science session at 8:30-9:15 AM EST on November 11.
  • As expected, there is significant risk with drug development and no guarantee that future studies will reflect similar results as presented at AHA.

FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition

Retrieved on: 
Monday, October 2, 2023
Senior, Novo Nordisk, Nordisk, PH1, Metabolic disorder, Research, Patient, PH, AUC, Liver, RNA interference, Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, DSM-IV codes, Pharmaceutical industry

We look forward to making our first RNAi treatment available to people living with PH1 and the healthcare professionals partnering on their care."

Key Points: 
  • We look forward to making our first RNAi treatment available to people living with PH1 and the healthcare professionals partnering on their care."
  • "Using the GalXC™ RNAi platform, RivflozaTM targets the liver-specific lactate dehydrogenase enzyme, which is the final step of oxalate production in PH1."
  • RivflozaTM, the first RNAi therapeutic by Novo Nordisk, was developed using the proprietary GalXCTM RNAi technology platform.
  • It is not known if RivflozaTM is safe and effective in children younger than 9 years of age.

Team Novo Nordisk and Novo Nordisk confirm three-year renewal of historic partnership

Retrieved on: 
Monday, August 21, 2023
Insulin, Partnership, Diabetes, Nordisk, Athlete, Dream, Patient, Novo Nordisk, Team Novo Nordisk, Sport, GP Kranj, Dentistry, Pharmaceutical industry, Management

ATLANTA, Aug. 21, 2023 /PRNewswire-PRWeb/ -- The world's only all-diabetes professional cycling team is excited to confirm the extension of their successful partnership with principal sponsor Novo Nordisk for another three years carrying Team Novo Nordisk into 2026.

Key Points: 
  • ATLANTA, Aug. 21, 2023 /PRNewswire-PRWeb/ -- The world's only all-diabetes professional cycling team is excited to confirm the extension of their successful partnership with principal sponsor Novo Nordisk for another three years carrying Team Novo Nordisk into 2026.
  • In 2021, Novo Nordisk & Team Novo Nordisk celebrated the discovery of insulin.
  • This year, they celebrate their 10-year partnership anniversary as well as the 100th year anniversary of Novo Nordisk.
  • Team Novo Nordisk is a testament to all the employees of Novo Nordisk that live and breathe the ethos of doing what is best for people living with diabetes or with another chronic condition.

NextMed Highlights Revolutionary Findings: Wegovy's Potential in Reducing Cardiovascular Risks by 20%

Retrieved on: 
Thursday, August 10, 2023
Weight, Obesity, Prevalence, Diabetes, Novo Nordisk, Classification, Stroke, Nordisk, Policy Studies Organization, Weight loss, Splenic infarction, Sleep apnea, Research, Medicine, Patient, SELECT, Risk, Overweight, Deep diving, Ageing, R, Health, Chronic kidney disease, Pharmaceutical industry, Dietary supplement, Medical imaging, Nursing

Given the global prevalence of obesity and its associated health risks, the demand for comprehensive and effective treatments has never been higher.

Key Points: 
  • Given the global prevalence of obesity and its associated health risks, the demand for comprehensive and effective treatments has never been higher.
  • Recognized for its weight loss properties, recent findings indicate its potential to notably reduce the risk of critical cardiovascular events.
  • The notable improvement in cardiovascular health, even for those without diabetes, indicates that Wegovy's benefits extend beyond just weight reduction, offering deeper metabolic and cardiovascular enhancements.
  • With the emerging data on Wegovy, NextMed foresees increased interest in consultations related to weight management and cardiovascular health.

Ginkgo Bioworks Advances Collaboration with Novo Nordisk on Expression Systems for Pharmaceutical Products

Retrieved on: 
Tuesday, July 11, 2023
DNA, Partnership, Obesity, Senior, Diabetes, Nordisk, Ginkgo, Patient, Engineering, Novo Nordisk, Conditional sentence, NYSE, Pharmaceutical industry

BOSTON, July 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products.

Key Points: 
  • BOSTON, July 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products.
  • Achievement of the first milestone included extensive modification and testing of a microbial expression system to understand the impact of the modifications on key performance parameters.
  • "This progress is a strong indicator of the potential we have to engineer biological systems that will expand the chemical space of biological medicines."
  • We believe this work will enable us to support even more pharmaceutical products, helping to achieve better outcomes for patients."

New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials

Retrieved on: 
Saturday, June 24, 2023
Injection, Insulin, American Diabetes Association, Nordisk, Type 2 diabetes, US, Blood, Hypoglycemia, Patient, SAN, Novo Nordisk, ADA, Glycated hemoglobin, Medical device, Pharmaceutical industry

Comparable Time below Range (blood glucose

Key Points: 
  • Comparable Time below Range (blood glucose
  • "A once-weekly basal insulin has the potential to change how we treat people with type 2 diabetes needing basal insulin replacement."
  • In ONWARDS 3, level 2 or 3 hypoglycemia rates were numerically higher with once-weekly insulin icodec vs. once-daily insulin degludec.
  • If approved, insulin icodec will represent the first and only once-weekly basal insulin option for adults with diabetes, addressing an unmet need in treatment vs. a daily basal insulin option4-9.

Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.

Retrieved on: 
Monday, June 5, 2023
Medical Devices, Health, Diabetes, Research, Science, Biotechnology, Prejudice, McDermott Will & Emery, BIO, Insulin, Obesity, ALCOR, Sale, EUR, Bird & Bird, Documentation, Acquisition, Lazard, Patient, Blood, AMF, Conditional sentence, Device, Security (finance), Pharmaceutical industry, Management, Stifel, Nordisk, Euronext, Novo Nordisk, Mallya

“We are delighted by the potential to join Novo Nordisk, a leading global healthcare company.

Key Points: 
  • “We are delighted by the potential to join Novo Nordisk, a leading global healthcare company.
  • Our teams are enthusiastic about pursuing this public health mission, which will be intensified by the strength of Novo Nordisk's global presence” said Eric Dessertenne, CEO of BIOCORP.
  • Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries.
  • 3 On the basis of a share capital as at 31 May 2023 of 4,412,286 actions representing 6,427,898 theoretical voting rights.

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

Retrieved on: 
Monday, May 1, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Other Health, Bluebird bio, Nordisk, Factor VIII, Gene editing, Disclosure, Haemophilia, Coagulopathy, Messenger, Research and development, Office of Rare Diseases Research, Development, Patient, Vivo, Novo Nordisk, LNP, Megat Burhainuddin, Genome, Pharmaceutical industry, Vaccine

The milestone is a result of delivering key pre-clinical proof of concept data that the Company plans to present during a virtual Research and Development deep dive on May 19, 2023.

Key Points: 
  • The milestone is a result of delivering key pre-clinical proof of concept data that the Company plans to present during a virtual Research and Development deep dive on May 19, 2023.
  • “We are excited about the continued progress in this program based on our internally developed in vivo gene editing platform.
  • 2seventy bio is responsible for megaTAL development and expression using their in vivo mRNA platform.
  • 2seventy bio will host a virtual R&D deep dive on Friday, May 19, from 10:00 a.m. – 11:30 a.m.

FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

Retrieved on: 
Thursday, January 5, 2023
IPSC, GMP, Research, Cellular Dynamics International, Potency (pharmacology), Novo Nordisk, Disease, Conditional sentence, Cell, Pharmaceutical industry, Nordisk

MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

Key Points: 
  • MADISON, Wis., Jan. 05, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.
  • Under the agreement, Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies.
  • “FUJIFILM Cellular Dynamics is a global leader in the development and manufacturing of GMP-grade iPSCs for cell therapy applications.
  • Our goal is to drive the iPSC field forward by building strategic partnerships,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics.

Novo Nordisk & ATLATL announce winners in their joint program EntreStar

Retrieved on: 
Monday, December 5, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Other Health, Therapy, B cell, Peking University, Conditional sentence, CNY, Pharmacology, Drug discovery, DNA, Novo Nordisk, Research, GMP, Element, D, Mentorship, Diabetes, Cancer, Government, Multimedia, RNA editing, Nordisk, Boya, RNA, Fine chemical, Pharmaceutical industry, Medical device

Novo Nordisk Research Centre China (NNRCC) and ATLATL jointly announce the winners of EntreStar program.

Key Points: 
  • Novo Nordisk Research Centre China (NNRCC) and ATLATL jointly announce the winners of EntreStar program.
  • As a Novo Nordisk affiliate in China, we partner with brilliant minds via INNOVO program to facilitate translational research, with EntreStar initiative as its latest addition.
  • Dr. Pengcheng ZHU, Founder of ATLATL Innovation Center, commented on the role ATLATL plays: It is my greatest pleasure to help make the EntreStar winners thrive at ATLATLs platform, with access to global resources, such as our partners like Novo Nordisk.
  • For more details on EntreStar, click here: 2022 EntreStar Open Call (novonordisk.com.cn)
    The ATLATL Innovation Center is a world-class scientific hub for global life sciences.